North Star Investment Management Corp. boosted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 5.5% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 70,062 shares of the company’s stock after acquiring an additional 3,674 shares during the period. Johnson & Johnson comprises about 0.9% of North Star Investment Management Corp.’s investment portfolio, making the stock its 19th biggest holding. North Star Investment Management Corp.’s holdings in Johnson & Johnson were worth $10,860,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently bought and sold shares of the company. Veracity Capital LLC boosted its stake in Johnson & Johnson by 1.2% in the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after purchasing an additional 59 shares during the period. LCM Capital Management Inc boosted its stake in Johnson & Johnson by 0.7% in the 4th quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock worth $1,667,000 after purchasing an additional 61 shares during the period. Arbor Investment Advisors LLC boosted its stake in Johnson & Johnson by 2.3% in the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock worth $476,000 after purchasing an additional 61 shares during the period. Sierra Capital LLC boosted its stake in Johnson & Johnson by 0.6% in the 4th quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock worth $1,773,000 after purchasing an additional 61 shares during the period. Finally, Retirement Planning Group boosted its stake in shares of Johnson & Johnson by 1.8% during the 4th quarter. Retirement Planning Group now owns 3,437 shares of the company’s stock valued at $607,000 after buying an additional 62 shares during the period. Institutional investors own 67.57% of the company’s stock.
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $170.19 on Monday. The firm’s 50-day moving average is $160.37 and its 200-day moving average is $161.25. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The company has a market cap of $442.28 billion, a price-to-earnings ratio of 34.45, a PEG ratio of 2.88 and a beta of 0.55.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be issued a dividend of $1.19 per share. The ex-dividend date is Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.80%. Johnson & Johnson’s payout ratio is 96.36%.
Insider Activity
In other news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.20% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the stock. Morgan Stanley reissued an “equal weight” rating and set a $187.00 target price on shares of Johnson & Johnson in a research note on Friday. StockNews.com assumed coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating for the company. Atlantic Securities decreased their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research note on Wednesday, April 19th. Credit Suisse Group lifted their price objective on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday. Finally, TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Eight research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $171.40.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- MarketBeat Week in Review – 7/17 – 7/21
- U.S. Bancorp Shares Rally As Analysts Get Bullish After Q2 Report
- AutoNation Beats Earnings Expectations, Stock Down?
- American Express Hiccups After Earnings, Time To Buy?
- ISRG Stock Sinks After Strong Earnings: Is the Growth Priced In?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
